18+ · Research Use Only · Not for Human Consumption
The GLP-1 landscape in the Philippines: 2026.
One receptor family reshaped metabolic research in under a decade. The three compounds that define it, the trial numbers behind each, and how the Philippine market actually splits.
Three compounds, three generations
Semaglutide is the original blockbuster: a pure GLP-1 receptor agonist that posted a 14.9% mean weight reduction at 68 weeks in STEP 1, published in NEJM in 2021. That number made the field. Every compound since has been measured against it.
Tirzepatide added a second receptor, GIP, and moved the benchmark. SURMOUNT-1, published in NEJM in 2022, reported 22.5% at 72 weeks. The head-to-head question got a direct answer in SURMOUNT-5, which compared the two and favored tirzepatide. Retatrutide added a third receptor, glucagon, and its Phase 2 trial (Jastreboff et al., NEJM 2023) reported 24.2% at 48 weeks. That is a Phase 2 figure against two Phase 3 figures, a distinction that matters, but the direction of travel is unmistakable: each added mechanism has moved the ceiling.
How the Philippine market splits
Locally the field divides into two markets that barely touch. The pharmacy market carries approved branded injectables, prescription-gated, at monthly costs that run into five figures in pesos. It serves patients under physician care, which is exactly what it is built for. The research market carries the same molecules as lyophilized vials for laboratory use, at a fraction of the price and with no therapeutic claim attached.
The Primara Labs catalogue reflects that second market. Retatrutide 10mg stocks at ₱2,790, or ₱2,510 on a first order. Tirzepatide 10mg lists at ₱2,500, ₱2,250 first order, and is in stock from local storage. Both ship from Metro Manila cold storage, same-day across the metro on verified orders before noon. The full comparison of what differs between pen and vial is in the research-grade vs pharmacy guide.
What 2026 is waiting on
The open question of 2026 is retatrutide's Phase 3 program, TRIUMPH, which is ongoing. If the Phase 2 number holds at scale, the three-generation pattern completes and the triple agonist becomes the new reference point. If it slips, tirzepatide keeps the crown for a while longer. Either way the research literature gets richer, which is what matters for laboratory work.
Beyond the big three, the wider pipeline is crowded with next-generation incretin candidates from multiple manufacturers, most still deep in trials. None of them has published data that displaces the compounds above. For a Philippine research buyer in 2026, the practical field is semaglutide in pharmacies, and tirzepatide and retatrutide as research vials. The regulatory backdrop is covered in the 2026 regulation status post.
Supplied for laboratory research use only. Not for human consumption. Nothing on this page is medical advice.
GLP-1 landscape questions
Which GLP-1 compound has the best published trial result?
Among published data, retatrutide leads with a 24.2% mean weight reduction at 48 weeks in Phase 2 (NEJM 2023), ahead of tirzepatide's 22.5% at 72 weeks in SURMOUNT-1 and semaglutide's 14.9% at 68 weeks in STEP 1. Retatrutide's figure is Phase 2, the other two are Phase 3.
What GLP-1 options exist in the Philippines in 2026?
Pharmacy channels carry branded pens at five-figure monthly peso costs, prescription required. The research market carries vials: retatrutide 10mg at ₱2,510 first order and tirzepatide 10mg at ₱2,250 first order, both for laboratory research use only.
Did tirzepatide really beat semaglutide head to head?
Yes. SURMOUNT-5 compared the two directly and favored tirzepatide on weight reduction, consistent with the gap between their earlier standalone trials.
Is semaglutide available as a research vial from Primara Labs?
No. The catalogue carries retatrutide and tirzepatide. Semaglutide remains widely available through pharmacy channels, which is where its market has settled.